A5056443688- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Radiopharmaceutical Chemistry and Applications
- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- Single-cell and spatial transcriptomics
- T-cell and B-cell Immunology
- Lung Cancer Treatments and Mutations
- Nanoplatforms for cancer theranostics
- Gene Regulatory Network Analysis
Université Claude Bernard Lyon 1
2022-2025
Centre Léon Bérard
2022-2025
Inserm
2021-2025
Centre de Recherche en Cancérologie de Lyon
2022-2025
Centre National de la Recherche Scientifique
2022-2025
University of Geneva
2024
Cancer Research Center
2022-2023
Université Clermont Auvergne
2021
Imagerie Moléculaire et Stratégies Théranostiques
2020
Background The efficacy of immunotherapies in metastatic melanoma depends on a robust T cell infiltration. Oncogenic alterations tumor cells have been associated to exclusion. Identifying novel cancer cell-intrinsic non-genetic mechanisms immune escape, the targeting which would reinstate recruitment, allow restore response anti-programmed death protein 1 (PD-1) antibody therapy. epithelial-to-mesenchymal transition (EMT)-inducing transcription factor ZEB1 is major regulator plasticity,...
Abstract Cell plasticity sustains intra-tumor heterogeneity and treatment resistance in melanoma. Deciphering the transcriptional mechanisms governing reversible phenotypic transitions between proliferative/differentiated invasive/stem-like states is required. Expression of ZEB1 transcription factor frequently activated melanoma, where it fosters adaptive to targeted therapies. Here, we performed a genome-wide characterization targets, by combining ChIP-sequencing RNA-sequencing, upon...
Abstract Dendritic cells (DCs) are promising targets for cancer immunotherapies because of their central role in the initiation and control immune responses. The rare cDC1 population is particular interest its remarkable ability to cross-present antigens (Ag) CD8+ T cells, promote Th1 cell polarization NK activation recruitment. However, spatial organization specific functions cDC1s response immunotherapy remain be clearly characterized human tumors. Here, we implemented a multiplexed...
Tumor cells can evade antitumor immune response by expressing the PD-L1 ligand, leading to inhibition of PD-1-expressing T lymphocytes. The mechanisms that regulate expression in cancer are imperfectly characterized. transcription factor ZEB1, a major regulator phenotype switching melanoma cells, was shown promote escape repressing cell infiltration. Using inducible models and ZEB1 gain/loss-of-function melanoma, we show binds CD274 (PD-L1) promoter, directly enhancing mRNA its at membrane....
<div>Abstract<p>Dendritic cells (DC) are promising targets for cancer immunotherapies because of their central role in the initiation and control immune responses. The type 1 conventional DC (cDC1) population is particular interest its ability to cross-present antigens CD8<sup>+</sup> T cells. cDC1s also secrete cytokines that allow Th1 cell polarization NK activation recruitment. However, spatial organization specific functions response immunotherapy remain be...
<p>Optimized immunofluorescence staining conditions for the multiplex panel</p>
<p>Description of the MELPREDICT cohort and design experiments performed in study.</p>
<p>Clinical features of MELPREDICT patients at baseline prior immunotherapy onset</p>
<p>Composition of DC aggregates and frequency in R NR patients.</p>
<p>Work flow analysis for the multiplexed immunofluorescence staining.</p>
Abstract Cell plasticity sustains intra-tumor heterogeneity and treatment resistance in melanoma. Deciphering the transcriptional mechanisms governing reversible phenotypic transitions between proliferative/differentiated invasive/stem-like states is required. Expression of ZEB1 transcription factor frequently activated melanoma, where it fosters adaptive to targeted therapies. Here, we performed a genome-wide characterization targets, by combining ChIP-sequencing RNA-sequencing, upon...
Purpose: To assess the efficiency of targeted radionuclide therapy (TRT), alone or in combination with MEK inhibitors (MEKi), melanomas harboring constitutive MAPK/ERK activation responsible for tumor radioresistance. Methods: For TRT, we used a melanin radiotracer ([131I]ICF01012) currently phase 1 clinical trial (NCT03784625). TRT combined MEKi was evaluated three-dimensional melanoma spheroid models human BRAFV600E SK-MEL-3, murine NRASQ61K 1007, and WT B16F10 melanomas. vivo...
Abstract Background Dendritic cells (DCs) are promising targets for cancer immunotherapies owing to their central role in the initiation and control of immune responses. Their functions encompass a wide range mechanisms mediated by different DC subsets. Several studies have identified human tumor- associated (TA-DC) populations through limited marker-based technologies, such as immunostaining or flow cytometry. However, tumor infiltration, spatial organization specific response immunotherapy...